會員登入
註冊
GlobalBio & Investment
Go Global and Beyond:
A Premier Biomedical Media in Taiwan
A Premier Biomedical Media in Taiwan
Taiwan’s research and development of rare disease drugs has yielded great results!
2024-03-31 / GlobalBio & Investment
#RareDiseaseBreakthroughsAmidstthepandemic,Taiwanesepharmaceuticalcompaniesdevelopingrarediseasedrugshavereportedpositiveresultsinclinicaltrials,leadingtoremarkablegrowthintheirstocks.Over30companiesi...
BRIM Biotechnology, Inc. announced its three focus areas for this year's operations
2024-02-28 / GlobalBio & Investment
#OphthalmologyInnovationGreatnewsfromBRIMBiotechnology,Inc.(6885.TWO)!Thecompanyhasannounceditsthreefocusareasforthisyear'soperations,whichinclude:1.ContinuingthedevelopmentofBRM421,theirleadasset...
Sartorius experts highlighted the key specifications of the new PIC/S GMP Annex 1 regulation
2024-02-28 / GlobalBio & Investment
#BiotechInsightsExcitingupdatesfromSartoriusandAdimmuneCorp(4142)'scorporateseminar!Sartoriusexperts,Tse-WeiChenandRZLin,highlightedthelatesttrendsincellculturedevelopmentandthekeyspecificationsof...
AnHorn partnered with European startups to explore new treatment targets for prostate cancer
2024-02-28 / GlobalBio & Investment
#InnovativeCollaborationAnHornMedicines,anAI-drivendrugdiscoverycompanyfocusedonproteindegradation,haspartneredwithEuropeanstartupstoexplorenewtreatmenttargetsforprostatecancer.On20February2024,Anhorn...
PharmaEssentia and Oneness Biotech Co Ltd have been honored in Sustainability Yearbook 2024
2024-02-28 / GlobalBio & Investment
#ESGExcellenceExcitingnews!PharmaEssentia(TPE:6446)andOnenessBiotechCoLtd(TPE:4743)havebeenhonoredintheprestigiousSustainabilityYearbook2024byS&PGlobalRatings.PharmaEssentiamarksahistoricmomentast...
How does medical technology revolutionize commercial health insurance?
2024-02-28 / GlobalBio & Investment
#MedicalInsuranceDidyouknowthattheaveragepersoninTaiwanhasthreeinsurancepolicies?Withtheriseofemergingmedicaltechnology,commercialhealthinsuranceisbeingrevolutionized.In2023,theBio-TaiwanCommittee(#BT...
Leadgene Biomedical, Inc.'s LEADGENE® IS ELISA Kit has been approved by Taiwan's FDA...
2024-02-28 / GlobalBio & Investment
#TFDAApprovalExcitingnews!LeadgeneBiomedical,Inc.'sLEADGENE®IndoxylSulfate(IS)ELISAKit,aCE-markedprotein-boundtoxindiagnosiskit,hasbeenapprovedbyTaiwan'sFDAasaClassIIIinvitrodiagnosticdevi...
Nine biopharma companies have announced record-high revenues for January
2024-02-28 / GlobalBio & Investment
#BiotechGrowthExcitingnewsfromthe#biopharmasector!Ninebiopharmacompanieshaveannouncedrecord-highrevenuesforJanuary,indicatingaprosperousstarttotheyear.Amongthem,AnxoPharmaceuticalTaiwanCo.Ltd(6677.TWO...
FDA approves Onivyde® as a first-line therapy for metastatic pancreatic adenocarcinoma
2024-02-28 / GlobalBio & Investment
**#FDAApproval**ExcitingnewsforPharmaEngineInc(4162.TWO)!FDAapproves#Onivyde®asafirst-linetherapyformetastaticpancreaticadenocarcinoma,markingapotentialnewstandardofcare.PharmaEngine'scollabor...
The potential of next-generation microbiome therapy in clinical applications (8th AMC)
2024-02-28 / GlobalBio & Investment
*#MicrobiomeTherapy**Canthegutmicrobiotarevolutionizecancertreatment?Insightsfromthe8thAsiaMicrobiomeConference(#AMC),heldbyIBCAcademiaSinica,NationalTaiwanUniversityHospital,and圖爾思生物科技BIOTOOLSCO.,LTD...
Chang Gung Medical Foundation teams up with Gilead Sciences to accelerate early-stage clinical trial
2024-02-28 / GlobalBio & Investment
**#ClinicalTrials**ChangGungMedicalFoundationteamsupwithGileadSciencestoaccelerateearly-stageclinicaltrials,focusingon#oncology.Thecollaborationaimstoadvanceclinicaltrialsintumorresearch,preclinicalco...
GBI Spotlight: Dr. Han-Chung Wu
2024-02-28 / GlobalBio & Investment
#GBISpotlight:Dr.Han-ChungWu(吳漢忠)MeetDr.Han-ChungWu,themanbehindthedevelopmentofprecisiontherapythroughinnovativephagedisplaytechnology.AstheDirectorofBioTrecatNBRP,AcademiaSinica,heisawell-knownfigur...
